How MIT's Whiteboard Scribbles Revolutionized Bladder Cancer Treatment

MIT researchers developed a device for targeted bladder cancer drug delivery, leading to the creation of TARIS Biomedical, which was later acquired by Johnson & Johnson. The device, designed to integrate with existing urological procedures, delivers medication directly to the bladder over two weeks and is removed with a standard cystoscope. Clinical trials showed that over 80 percent of high-risk, non-muscle-invasive bladder cancer patients had no evidence of disease after treatment, with more than half remaining cancer-free at nine months. The system received FDA approval and is being considered for use in other diseases.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.